Evoke Pharma (NASDAQ:EVOK) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Monday.
EVOK has been the topic of several other research reports. Zacks Investment Research upgraded shares of Evoke Pharma from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research report on Tuesday, May 8th. HC Wainwright set a $9.00 price target on shares of Evoke Pharma and gave the stock a “buy” rating in a research report on Monday, April 2nd. Finally, B. Riley restated a “buy” rating and issued a $5.00 price target (down previously from $10.00) on shares of Evoke Pharma in a research report on Thursday, March 8th. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating to the company. Evoke Pharma has an average rating of “Hold” and a consensus price target of $7.83.
EVOK traded down $0.02 during trading hours on Monday, hitting $2.48. The company’s stock had a trading volume of 12,442 shares, compared to its average volume of 63,523. Evoke Pharma has a 12 month low of $1.85 and a 12 month high of $4.09. The stock has a market capitalization of $41.94 million, a PE ratio of -2.99 and a beta of 1.42.
Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings results on Wednesday, May 16th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.06. analysts anticipate that Evoke Pharma will post -0.51 earnings per share for the current year.
An institutional investor recently bought a new position in Evoke Pharma stock. 683 Capital Management LLC acquired a new stake in shares of Evoke Pharma Inc (NASDAQ:EVOK) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 114,300 shares of the specialty pharmaceutical company’s stock, valued at approximately $258,000. 683 Capital Management LLC owned about 0.74% of Evoke Pharma as of its most recent SEC filing. 13.64% of the stock is owned by institutional investors and hedge funds.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is in Phase 2b clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.